Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of Hypertension.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 17 05 2020
accepted: 23 07 2020
entrez: 6 10 2020
pubmed: 7 10 2020
medline: 28 10 2020
Statut: epublish

Résumé

The global rate of intensive care unit (ICU) admission during the COVID-19 pandemic varies within countries and is among the main challenges for health care systems worldwide. Conflicting results have been reported about the response to coronavirus infection and COVID-19 outcomes in men and women. Understanding predictors of intensive care unit admission might be of help for future planning and management of the disease. We designed a cross-sectional observational multicenter nationwide survey in Italy to understand gender-related clinical predictors of ICU admission in patients with COVID-19. We analyzed information from 2378 charts of Italian patients certified for COVID-19 admitted in 26 hospitals. Three hundred ninety-five patients (16.6%) required ICU admission due to COVID19 infection, more frequently men (74%), with a higher prevalence of comorbidities (1,78±0,06 vs 1,54±0,03 p<0.05). In multivariable regression model main predictors of admission to ICU are male gender (OR 1,74 95% CI 1,36-2,22 p<0.0001) and presence of obesity (OR 2,88 95% CI 2,03-4,07 p<0.0001), chronic kidney disease (OR: 1,588; 95%, 1,036-2,434 p<0,05) and hypertension (OR: 1,314; 95% 1,039-1,662; p<0,05). In gender specific analysis, obesity, chronic kidney disease and hypertension are associated with higher rate of admission to ICU among men, whereas in women, obesity (OR: 2,564; 95% CI 1,336-4.920 p<0.0001) and heart failure (OR: 1,775 95% CI: 1,030-3,057) are associated with higher rate of ICU admission. Our study demonstrates that gender is the primary determinant of the disease's severity among COVID-19. Obesity is the condition more often observed among those admitted to ICU within both genders. Clinicaltrials.gov: NCT04331574.

Sections du résumé

BACKGROUND
The global rate of intensive care unit (ICU) admission during the COVID-19 pandemic varies within countries and is among the main challenges for health care systems worldwide. Conflicting results have been reported about the response to coronavirus infection and COVID-19 outcomes in men and women. Understanding predictors of intensive care unit admission might be of help for future planning and management of the disease.
METHODS AND FINDINGS
We designed a cross-sectional observational multicenter nationwide survey in Italy to understand gender-related clinical predictors of ICU admission in patients with COVID-19. We analyzed information from 2378 charts of Italian patients certified for COVID-19 admitted in 26 hospitals. Three hundred ninety-five patients (16.6%) required ICU admission due to COVID19 infection, more frequently men (74%), with a higher prevalence of comorbidities (1,78±0,06 vs 1,54±0,03 p<0.05). In multivariable regression model main predictors of admission to ICU are male gender (OR 1,74 95% CI 1,36-2,22 p<0.0001) and presence of obesity (OR 2,88 95% CI 2,03-4,07 p<0.0001), chronic kidney disease (OR: 1,588; 95%, 1,036-2,434 p<0,05) and hypertension (OR: 1,314; 95% 1,039-1,662; p<0,05). In gender specific analysis, obesity, chronic kidney disease and hypertension are associated with higher rate of admission to ICU among men, whereas in women, obesity (OR: 2,564; 95% CI 1,336-4.920 p<0.0001) and heart failure (OR: 1,775 95% CI: 1,030-3,057) are associated with higher rate of ICU admission.
CONCLUSIONS
Our study demonstrates that gender is the primary determinant of the disease's severity among COVID-19. Obesity is the condition more often observed among those admitted to ICU within both genders.
TRIAL REGISTRATION
Clinicaltrials.gov: NCT04331574.

Identifiants

pubmed: 33022004
doi: 10.1371/journal.pone.0237297
pii: PONE-D-20-14687
pmc: PMC7537902
doi:

Banques de données

ClinicalTrials.gov
['NCT04331574']

Types de publication

Clinical Trial Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0237297

Commentaires et corrections

Type : ErratumIn
Type : ErratumIn

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Clin Microbiol Infect. 2020 Jun;26(6):767-772
pubmed: 32304745
High Blood Press Cardiovasc Prev. 2020 Apr;27(2):105-108
pubmed: 32266708
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Mayo Clin Proc. 2010 Sep;85(9):798-805
pubmed: 20664021
Eur J Heart Fail. 2020 Jun;22(6):957-966
pubmed: 32412156
Eur Heart J. 2020 May 14;41(19):1810-1817
pubmed: 32388565
Ann Am Thorac Soc. 2017 Nov;14(Supplement_5):S406-S409
pubmed: 29161078
Hypertension. 2020 Jun;75(6):1382-1385
pubmed: 32208987
PLoS Pathog. 2020 Apr 28;16(4):e1008520
pubmed: 32343745
Lancet Respir Med. 2020 Apr;8(4):e20
pubmed: 32171067
Hypertension. 2020 Aug;76(2):366-372
pubmed: 32564693
N Engl J Med. 2020 Jun 25;382(26):2582
pubmed: 32501665
PLoS Pathog. 2020 Jun 22;16(6):e1008570
pubmed: 32569293
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Obesity (Silver Spring). 2020 Jul;28(7):1195-1199
pubmed: 32271993
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
J Clin Med. 2020 Mar 30;9(4):
pubmed: 32235486
Cells. 2019 Aug 09;8(8):
pubmed: 31405024
J Cell Physiol. 2018 Jan;233(1):88-97
pubmed: 28181253
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Circulation. 2020 Jul 7;142(1):4-6
pubmed: 32320270
J Immunol. 2017 May 15;198(10):4046-4053
pubmed: 28373583
Arch Acad Emerg Med. 2020 Mar 24;8(1):e35
pubmed: 32232218
J Virol. 2011 Dec;85(24):13363-72
pubmed: 21994442
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Aging (Albany NY). 2019 Apr 8;11(7):1918-1933
pubmed: 30964749
BMJ. 2020 Apr 3;369:m1366
pubmed: 32245830
Lancet. 2020 Feb 22;395(10224):e40
pubmed: 32035511
Am Fam Physician. 2009 Dec 1;80(11):1254-8
pubmed: 19961138

Auteurs

Guido Iaccarino (G)

Dept. of Advanced Biomedical Sciences, Federico II University, Naples, Italy.

Guido Grassi (G)

Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy.

Claudio Borghi (C)

Dept. of Medicine and Surgery Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.

Stefano Carugo (S)

Università degli Studi di Milano, Milano, Italy.

Francesco Fallo (F)

Clinica Medica 3, Department of Medicine (DIMED), University of Padova, Padova, Italy.

Claudio Ferri (C)

Dept. of Clinical Medicine, Public Health, Life and Environment Sciences, University of L'Aquila, L'Aquila, Italy.

Cristina Giannattasio (C)

Cardiology 4, "A. De Gasperis" Department, ASST GOM Niguarda Ca' Granda Hospital, Milan, Italy.

Davide Grassi (D)

Dept. of Clinical Medicine, Public Health, Life and Environment Sciences, University of L'Aquila, L'Aquila, Italy.

Claudio Letizia (C)

Department of Translational and Precision Medicine, Unit of Secondary Arterial Hypertension, Policlinico "Umberto I", "Sapienza" University of Rome, Rome, Italy.

Costantino Mancusi (C)

Dept. of Advanced Biomedical Sciences, Federico II University, Naples, Italy.

Pietro Minuz (P)

Department of Medicine, Section of Internal Medicine C, University of Verona, Verona, Italy.

Stefano Perlini (S)

Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.

Giacomo Pucci (G)

Section of Internal Medicine Terni, Department of Medicine, University of Perugia, Terni, Italy.

Damiano Rizzoni (D)

Department of Clinical and Experimental Sciences, University of Brescia-Internal Medicine ASST Spedali Civili PO Montichiari, Brescia, Italy.

Massimo Salvetti (M)

Dept. of Clinical & Experimental Sciences, Medicina 2, ASST Spedali Civili Brescia, University of Brescia, Brescia, Italy.

Riccardo Sarzani (R)

Internal Medicine and Geriatrics, Department of Clinical and Molecular Sciences, Italian National Research Centre on Aging, Hospital "U. Sestilli", IRCCS-INRCA, University "Politecnica Delle Marche", Ancona, Italy.

Leonardo Sechi (L)

Department of Medicine, University of Udine, Udine, Italy.

Franco Veglio (F)

Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Turin, Turin, Italy.

Massimo Volpe (M)

Clinical and Molecular Medicine Department, Rome and IRCCS Neuromed, Sapienza University Sant'Andrea Hospital, Pozzilli (IS), Italy.

Maria Lorenza Muiesan (ML)

Dept. of Clinical & Experimental Sciences, Medicina 2, ASST Spedali Civili Brescia, University of Brescia, Brescia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH